Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in Active Noninfectious Intermediate, Posterior, or Panuveitis
NCT07861074Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Jun 2029
01
Overview
A Phase 2 trial of tulisokibart in uveitis, sponsored by Merck & Co.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tulisokibart
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT07861074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861074.